18F-JNJ-64413739:P2X7离子通道新型PET配体的辐射剂量学、动力学建模、重测变异性及P2X7拮抗剂JNJ-54175446的占位
本研究在健康男性志愿者中评估了P2X7特异性PET配体18F-JNJ-64413739的辐射剂量学、动力学模型、重测变异性及P2X7拮抗剂JNJ-54175446的占位。结果表明该配体适用于人脑P2X7R表达的定量,可用于评估P2X7拮抗剂的靶点结合及指导剂量选择。
要点
- 平均有效剂量为22.0 ± 1.0 μSv/MBq。
- 两组织室模型为最适动力学模型, Logan图形分析结果与之非常相似。
- 单次口服JNJ-54175446剂量高于50 mg时,P2X7占位接近饱和。
核心结论
- 18F-JNJ-64413739是适用于人脑P2X7R表达定量的PET配体,可用于了解健康和疾病状态下的P2X7R表达、评估P2X7拮抗剂的靶点结合以及指导剂量选择。
研究设计与样本
- 在3名健康男性受试者中通过连续全身PET/CT扫描进行全身剂量学评估,使用OLINDA(v1.1)计算有效剂量。
- 5名健康男性受试者接受120分钟动态18F-JNJ-64413739 PET/MRI扫描并动脉采血,以确定合适的动力学模型。
- 其中4名受试者重复PET/MRI扫描以评估中期重测变异性(扫描间隔26-97天)。
- 在单剂量占位研究中,8名健康男性受试者在单次口服JNJ-54175446(剂量范围5-300 mg)后4-6小时接受基线和给药后18F-JNJ-64413739 PET/MRI扫描。
主要发现
- 平均(均值 ± 标准差)有效剂量为22.0 ± 1.0 μSv/MBq。
- 两组织室模型为最适动力学模型,Logan图形分析显示非常相似的结果。
- 区域两组织室模型VT值约为3,在所有脑区分布较均匀,丘脑、纹状体和脑干的估计值略高。
- 受试者间VT变异性相对较高,皮层VT在受试者间显示约3倍范围。
- 采集时间可缩短至90分钟;区域重测变异性平均值两组织室模型VT为10.7% ± 2.2%,Logan图形分析VT为11.9% ± 2.2%;单次JNJ-54175446剂量高于50 mg时P2X7占位接近饱和,未识别出参考区域。
关键数值与推荐
- 平均有效剂量为22.0 ± 1.0 μSv/MBq(3名健康男性受试者)。
- 区域两组织室模型VT值约为3,丘脑、纹状体和脑干的估计值略高。
- 皮层VT在受试者间显示约3倍范围。
- 采集时间可缩短至90分钟。
- 区域重测变异性平均值两组织室模型VT为10.7% ± 2.2%,Logan图形分析VT为11.9% ± 2.2%(4名受试者,扫描间隔26-97天)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 受试者间VT变异性相对较高,皮层VT显示约3倍范围。
- 未识别出参考区域。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The P2X7 receptor (P2X7R) is an adenosine triphosphate-gated ion channel that is predominantly expressed on microglial cells in the central nervous system. We report the clinical qualification of P2X7-specific PET ligand 18F-JNJ-64413739 in healthy volunteers, including dosimetry, kinetic modeling, test-retest variability, and blocking by the P2X7 antagonist JNJ-54175446. Methods: Whole-body dosimetry was performed in 3 healthy male subjects by consecutive whole-body PET/CT scanning, estimation of the normalized cumulated activity, and calculation of the effective dose using OLINDA (v1.1). Next, 5 healthy male subjects underwent a 120-min dynamic 18F-JNJ-64413739 PET/MRI scan with arterial blood sampling to determine the appropriate kinetic model. For this purpose, 1- and 2-tissue compartment models and Logan graphic analysis (LGA) were evaluated for estimating regional volumes of distribution (VT). PET/MRI scanning was repeated in 4 of these subjects to evaluate medium-term test-retest variability (interscan interval, 26-97 d). For the single-dose occupancy study, 8 healthy male subjects underwent baseline and postdose 18F-JNJ-64413739 PET/MRI scans 4-6 h after the administration of a single oral dose of JNJ-54175446 (dose range, 5-300 mg). P2X7 occupancies were estimated using a Lassen plot and regional baseline and postdose VTResults: The average (mean ± SD) effective dose was 22.0 ± 1.0 μSv/MBq. The 2-tissue compartment model was the most appropriate kinetic model, with LGA showing very similar results. Regional 2-tissue compartment model VT values were about 3 and were rather homogeneous across all brain regions, with slightly higher estimates for the thalamus, striatum, and brain stem. Between-subject VT variability was relatively high, with cortical VT showing an approximate 3-fold range across subjects. As for time stability, the acquisition time could be reduced to 90 min. The average regional test-retest variability values were 10.7% ± 2.2% for 2-tissue compartment model VT and 11.9% ± 2.2% for LGA VT P2X7 occupancy approached saturation for single doses of JNJ-54175446 higher than 50 mg, and no reference region could be identified. Conclusion:18F-JNJ-64413739 is a suitable PET ligand for the quantification of P2X7R expression in the human brain. It can be used to provide insight into P2X7R expression in health and disease, to evaluate target engagement by P2X7 antagonists, and to guide dose selection.
引用
- Koole M, Schmidt ME, Hijzen A, et al. 18F-JNJ-64413739, a Novel PET Ligand for the P2X7 Ion Channel: Radiation Dosimetry, Kinetic Modeling, Test-Retest Variability, and Occupancy of the P2X7 Antagonist JNJ-54175446. J Nucl Med. 2018. PMID: 30262518. doi:10.2967/jnumed.118.216747
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。